Surgical Treatment of Canalicular Stenosis in Patients Receiving Docetaxel Weekly
Open Access
- 1 December 2001
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 119 (12) , 1802-1804
- https://doi.org/10.1001/archopht.119.12.1802
Abstract
DOCETAXEL (Taxotere; Aventis, Collegeville, Pa) is an effective chemotherapeutic agent against metastatic breast cancer.1-3 In women with metastatic disease, docetaxel is usually administered as a 1-hour intravenous infusion every 21 days. With this standard administration schedule, the dose-limiting adverse effect is myelosuppression.4 Weekly administration of docetaxel has been studied in phase I and II trials and has proven to be a less myelosuppressive regimen.5,6Keywords
This publication has 3 references indexed in Scilit:
- Docetaxel Administered on a Weekly Basis for Metastatic Breast CancerJournal of Clinical Oncology, 2000
- Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.Journal of Clinical Oncology, 1998
- Docetaxel.Journal of Clinical Oncology, 1995